U.S. markets closed
  • S&P Futures

    4,472.00
    -2.25 (-0.05%)
     
  • Dow Futures

    34,738.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    15,506.00
    -11.75 (-0.08%)
     
  • Russell 2000 Futures

    2,230.60
    -2.60 (-0.12%)
     
  • Crude Oil

    72.57
    -0.04 (-0.06%)
     
  • Gold

    1,756.80
    +0.10 (+0.01%)
     
  • Silver

    22.84
    +0.05 (+0.22%)
     
  • EUR/USD

    1.1769
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.3310
    +0.0270 (+2.07%)
     
  • Vix

    18.69
    +0.51 (+2.81%)
     
  • GBP/USD

    1.3789
    -0.0008 (-0.06%)
     
  • USD/JPY

    109.8810
    +0.1630 (+0.15%)
     
  • BTC-USD

    47,860.43
    -50.92 (-0.11%)
     
  • CMC Crypto 200

    1,225.34
    -7.95 (-0.64%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,463.32
    +139.98 (+0.46%)
     

Renalytix AI plc (“RenalytixAI” or the “Company”) Change of adviser

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Investec Bank plc as joint corporate broker, with immediate effect to work alongside its existing nominated adviser and joint broker, Stifel.

For further information, please contact:

Renalytix AI plc

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Daniel Adams

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com.